Problems that Physicians should Notice for Better Treatment of Hypercholesterolemia in Japan

Yoshio Fujioka
Division of Clinical Nutrition, Faculty of Nutrition, Kobe Gakuin University, Kobe, Japan

Regulation of serum lipid profiles, especially low-density lipoprotein-cholesterol (LDL-C) levels, is receiving remarkable attention from not only medical experts but also general public. Then, even after providing LDL-C lowering therapy, residual risk sometimes comes to an issue for further reduction of atherosclerotic cardiovascular diseases (ASCVD). However, the means to reduce LDL-C levels and the ideal target level of LDL-C are still the most important themes. To promote effective lipid management in Japan, Japanese Atherosclerosis Society (JAS) continuously recommends ways to treat dyslipidemia and proposes the specific target levels of LDL-C, which are also published in the newest guideline 20171). However, in the cohort of patients with high cardiovascular risk in 2013, Teramoto et al. reported that approximately 68% of the overall population achieved guideline that recommended levels of LDL-C with only 42% receiving current treatment with statins2).

Recently, Yamashita et al. reported the current status of physician awareness and attitudes for lipid-lowering therapy3). In January 2017, authors conducted web-based survey in 500 Japanese physicians, 100 in each of five categories: cardiology; diabetes, metabolism, and endocrinology; neurology/neurosurgery/stroke medicine; general internal medicine (hospitals ≥ 20 beds); and general internal medicine (self-employed practitioners at clinics or small hospitals ≤ 19 beds). This survey revealed three important problems. First, there exists a difference among physicians in their specialties about the target LDL-C level. Second, the general physicians in Japan may be treating undiagnosed familial hypercholesterolemia (FH) patients. Third, there is a low rate in the use of non-HDL-C level and the risk management chart.

At first, essentially, most physicians (over 95%) recognized high LDL-C level as an important risk for ASCVD. The mean target level for physicians with expertise in cardiology was the lowest of all the areas of clinical expertise (92.6±17.3 mg/dL), and in patients with a history or complications of diabetes, chronic kidney disease, noncardiogenic cerebral infarction, or peripheral arterial disease, the overall target level was 112.7±17.4 mg/dL.

As for the statin therapy, participants were most concerned about muscle disorders as adverse effect, followed by new onset diabetes. In addition, physicians with expertise in neurology/neurosurgery/stroke were about twice as likely as other participants to agree with the statement “Japanese with low LDL-C are more likely to develop cerebral hemorrhage”, while over 70% of participants expressed concern about safety at LDL-C below 70 mg/dL.

The authors stated that cardiology specialists tend to practice lipid-lowering treatment more aggressively than those with other areas of medical expertise, which may be because they generally treat secondary prevention patients and that the increasing number of patients who are candidates for secondary prevention of ASCVD could predispose these specialists to develop a mindset toward ASCVD therapy similar to that seen in the US and Europe. In addition, they suggested that less aggressive LDL-C target setting by the physicians with expertise in neurology/neurosurgery/stroke might be partially related to their sense that the Japanese patients are generally at low risk for CV events even without achieving the currently recommended lipid levels. These results and comments may faithfully reflect current opinion of Japanese physicians and suggest several issues to overcome against the low rate of treatment for hypercholesterolemia.

Next, 65.4% of participants had treated patients with FH, but the percentage was lower in physicians...
References

1) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, and Yamashita S; Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984

2) Teramoto T, Uno K, Miyoshi I, Khan I, Gorcyca K, Sanchez RJ, Yoshida S, Kawatari K, Masaki T, Arai H, Yamashita S. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis, 2016; 251: 248-254

3) Yamashita S, Masuda D, Arai H, Matsuzawa Y. Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes. J Atheroscler Thromb, 2019; 26: 154-169

4) Teramoto T, Kai T, Crawford B, Arai H, Yamashita S. Treatment patterns and lipid profile in patients with familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2018; 25: 580-592

5) Michikura M, Oghara M, Yamamoto M, Sekimoto M, Fuke C, Hori M, Arai K, Kihara S, Hosoda K, Yanagi K, Harada-Shiba M. Achilles Tendon Ultrasonography for Diagnosis of Familial Hypercholesterolemia Among Japanese Subjects. Circ J, 2017; 81: 1879-1885

6) Tsuji M, Arima H, Ohkubo T, Nakamura K, Takezaki T, Sakata K, Okuda N, Nishi N, Kadota A, Okamura T, Ueshima H, Okayama A, Miura K, for the NIPPON DATA 2010 Research Group. Socioeconomic status and knowledge of cardiovascular risk factors: NIPPON DATA2010. J Epidemiol, 2018; 28(Suppl 3): S46-S52

7) Fujiyoshi N, Arima H, Sato H, Ojima T, Nishi N, Okada N, Kadota A, Okubo T, Hozawa A, Nakaya N, Fujiyoshi A, Okamura T, Ueshima H, Okayama A, Miura K, NIPPON DATA2010 Research Group. Associations between socioeconomic status and the prevalence and treatment of hypercholesterolemia in a general Japanese population: NIPPON DATA2010. J Atheroscler Thromb, 2018; 25: 606-620

Conflict of Interest

None.